Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

Anyone following the rhetoric around <keyword id="107950" type="General" weightage="100" keywordseo="Artificial-Intelligence" source="Orion">artificial intelligence</keyword> in recent years has heard one version or another of the cl<keyword id="6355999" type="General" weightage="20" keywordseo="AI" source="Orion">ai</keyword>m that AI is inevitable. Common themes are that AI is already here and indispensable, and people who are bearish on it harm themselves. In the business world, AI advocates tell companies and workers that they will fall behind if they fail to integrate generative AI into their operations. In the sciences, AI advocates promise that AI will aid in curing hitherto intractable diseases. In higher education, AI promoters admonish teachers that students must learn how to use AI or risk becoming uncompetitive when it comes time to find a job. In national security, AI's champions say that either the nation invests heavily in AI weaponry, or it will be at a disadvantage against the Chinese and Russians, who are already doing so. The argument across these different domains is essentially the same: The time for AI skepticism has come and gone. The <keyword id="6355118" type="General" weightage="20" keywordseo="technology" source="Orion">technology</keyword> will shape the future, whether you like it or not. You have the choice to learn how to use it or be left out of that future. Anyone trying to stand in the technology's way is as hopeless as the manual weavers who resisted the mechanical looms in the early 19th century. In the past few years, my colleagues and I (Nir Eisikovits, Professor of Philosophy and Director, Applied Ethics Center, UMass Boston) have been studying the ethical questions raised by the widespread adoption of AI, and I believe the inevitability argument is misleading. <h2>History and hindsight</h2> This claim is the most recent version of a deterministic view of technological development. It's the belief that innovations are unstoppable once people start working on them. In other words, some genies don't go back in their bottles. The best you can do is harness them for your good purposes. This deterministic approach to tech has a long history. It's been applied to the influence of the printing press as well as to the rise of automobiles and the infrastructure they require, among other developments. But I believe that when it comes to AI, the technological determinism argument is both exaggerated and oversimplified. <h2>AI in the field(s)</h2> Consider the contention that businesses can't afford to stay out of the AI game. The case has yet to be made that AI is delivering significant productivity gains to the firms that use it. A report in The <keyword id="20856675" type="General" weightage="20" keywordseo="economist" source="keywords">Economist</keyword> in July 2024 suggests that so far, the technology has had almost no economic impact. AI's role in higher education is also still very much an open question. Though universities have, in the past two years, invested heavily in AI-related initiatives, evidence suggests they may have jumped the gun. The technology can serve as an interesting pedagogical tool. For example, creating a Plato chatbot that lets students have a text conversation with a bot posing as Plato is a cool gimmick. However, AI is already starting to displace some of the best tools teachers have for assessment and for developing critical thinking, such as writing assignments. The college essay is going the way of the dinosaurs as more teachers give up on the ability to tell whether their students are writing their papers themselves. What's the cost-benefit argument for giving up on writing, an important and useful traditional skill? In the sciences and medicine, the use of AI seems promising. Its role in understanding the structure of proteins, for example, will likely be significant for curing diseases. The technology is also transforming medical imaging and has been helpful in accelerating the drug discovery process. But the excitement can become exaggerated. AI-based predictions about which cases of COVID-19 would become severe have roundly failed, and doctors rely excessively on the technology's diagnostic ability, often against their own better clinical judgment. And so, even in this area, where the potential is great, AI's ultimate impact is unclear. In national security, the argument for investing in AI development is compelling. Since the stakes can be high, the argument that if the Chinese and the Russians are developing AI-driven autonomous weapons, the United States can't afford to fall behind has real purchase. But a complete surrender to this form of reasoning, though tempting, is likely to lead the <keyword id="19899807" type="General" weightage="20" keywordseo="u-s-" source="keywords">U.S.</keyword> to overlook the disproportionate impact of these systems on nations that are too poor to participate in the AI arms race. The major powers could deploy the technology in conflicts in these nations. And, just as significantly, this argument de-emphasizes the possibility of collaborating with adversaries on limiting military AI systems, favoring arms race over arms control.<h2> One step at a time</h2> Surveying the potential significance and risks of AI in these different domains merits some skepticism about the technology. I believe that AI should be adopted piecemeal and with a nuanced approach rather than subject to sweeping claims of inevitability. In developing this careful take, there are two things to keep in mind: -First, companies and entrepreneurs working on artificial intelligence have an obvious interest in the technology being perceived as inevitable and necessary, since they make a living from its adoption. It's important to pay attention to who is making claims of inevitability, and why. -Second, it's worth taking a lesson from recent history. Over the past 15 years, smartphones and the social media apps that run on them have come to be seen as a fact of life - a technology as transformative as it is inevitable. Then data started emerging about the <keyword id="6354774" type="General" weightage="20" keywordseo="mental-health" source="Orion">mental health</keyword> harms they cause teens, especially young girls. School districts across the United States started to ban phones to protect the attention spans and mental health of their students. And some people have reverted to using flip phones as a quality of life change to avoid smartphones. After a long experiment with the mental health of kids, facilitated by claims of technological determinism, Americans changed course. What seemed fixed turned out to be alterable. There is still time to avoid repeating the same mistake with artificial intelligence, which potentially could have larger consequences for society.

Is AI dominance inevitable? A technology ethicist says no, actually

<keyword id="3658" type="General" weightage="100" keywordseo="india" source="Orion">India</keyword> on Tuesday recorded 3038 fresh cases of covid in the last 24 hours with the active caseload standing at 21,179. The COVID cases in India have seen an upward trend in the past few days with the daily fresh infections ranging between 2,994 on April 1 to 3,824 on April 2 and 3,641 on April 3 now dropped to 3038 in the last 24 hours. With 2,069 recoveries in the last 24 hours, total recoveries have increased to 4,41,77,204. India's recovery rate is currently at 98.76 per cent. The daily and weekly positivity rates are 1.84 per cent and 2.49 per cent respectively. A total of 1,894 doses were administered in the last 24 hours. Of the 92.20 crore total tests conducted so far, 1,64,740 tests were conducted in the last 24 hours. Under the Nationwide Vaccination Drive, India has so far administered 220.65 crore Covid-19 <keyword id="24209" type="General" weightage="80" keywordseo="vaccine" source="Orion">Vaccine</keyword> doses (95.20 crores <keyword id="7334317" type="General" weightage="80" keywordseo="second-dose" source="Orion">Second Dose</keyword> and 22.86 crores <keyword id="12813770" type="General" weightage="80" keywordseo="precaution-dose" source="Orion">Precaution Dose</keyword>), of which 9,497 doses were administered in the last 24 hours. In the wake of rising COVID cases in India, Union Health Minister Mansukh Mandaviya on Monday said that Omicron's sub-variant which is circulating in the country has not led to an increase in hospitalisations and there is no need to worry. The Minister said that there is a need to remain vigilant. "We need to remain alert but there is no need to worry. Currently, the sub-variant of Omicron which is circulating in the country hasn't increased hospitalisations," Mandaviya said. The Ministry of Health and Family Welfare has issued revised guidelines for Covid-19 in the wake of the surge of cases in the past week across the country. "Antibiotics should not be used unless there is clinical suspicion of bacterial infection. The possibility of coinfection of COVID-19 with other endemic infections must be considered. Systemic corticosteroids are not indicated in mild disease," revised guidelines said. "Antibiotics should not be used unless there is clinical suspicion of bacterial infection. The possibility of coinfection of COVID-19 with other endemic infections must be considered. Systemic corticosteroids are not indicated in mild disease," revised guidelines said. "Seek immediate medical attention if difficulty breathing, High-grade fever/ severe cough, particularly if lasting for more than 5 days. A low threshold is to be kept for those with any of the high-risk features," guidelines discussed and prepared in January said. Additionally, in moderate or severe diseases at high risk of progression, the guidelines recommend, "Consider <keyword id="8775508" type="General" weightage="80" keywordseo="remdesivir" source="Orion">Remdesivir</keyword> for up to 5 days (200 mg IV on day 1 followed by 100 mg IV OD for the next 4 days)". SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/news/virat-kohli-ms-dhoni-rohit-sharma-rule-brand-endorsements-in-indian-sports-industry/articleshow/99237494.cms">With 30 brands each, Kohli, Dhoni &amp; Rohit Sharma rule Indian sports endorsements</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/health/news/harsh-discipline-with-young-children-can-lead-to-lasting-mental-health-problems-says-new-study/articleshow/99238367.cms">Harsh discipline with young children can lead to lasting mental health problems says new study</a>

Remain alert says Union Health Minister as India records 3,038 fresh Covid-19 cases

<keyword id="8775508" type="General" weightage="100" keywordseo="remdesivir" source="Orion">Remdesivir</keyword> can reduce mortality in patients if administered within 9 days of COVID-19 symptom onset, according to a study conducted on Asian patients. Researchers from Tokyo Medical and Dental University (TMDU) have found that treatment with remdesivir within 9 days of COVID-19 symptom onset decreases mortality in Asian patients also taking corticosteroids, the study said. Several studies, according to the study, have already shown that remdesivir can shorten recovery time in patients with COVID-19, although there are conflicting reports on whether the drug prevents patients from dying. In addition, previous trials did not focus on patients who required breathing support while in the <keyword id="47851" type="General" weightage="50" keywordseo="icu" source="Orion">ICU</keyword>. "Given the inconsistent evidence regarding the survival benefit it confers, we sought to investigate the effectiveness of remdesivir in patients with COVID-19, who were admitted to an ICU in Japan," said <keyword id="15594616" type="General" weightage="50" keywordseo="mariko-hanafusa" source="Orion">Mariko Hanafusa</keyword>, the first author of the study. "All of these patients were being treated with corticosteroids for pneumonia, and some were receiving mechanical assistance for breathing," said Hanafusa. According to the study, the researchers analyzed the medical records of 168 patients with COVID-19 admitted to the ICU at TMDU Hospital between April 2020 and November 2021. The patients were divided into groups based on whether or not they were also treated with remdesivir, the study, published in the Journal of Medical Virology, said. "The results showed a clear difference in patient survival based on when they received treatment with remdesivir," said <keyword id="15594615" type="General" weightage="50" keywordseo="takeo-fujiwara" source="Orion">Takeo Fujiwara</keyword>, senior author of the study. "In-hospital mortality rates were significantly lower in ICU patients who received remdesivir and corticosteroids within 9 days of symptom onset than in patients whose treatment with remdesivir started 10 or more days after they first developed symptoms," said Fujiwara. A small number of patients experienced adverse events such as a rash, requiring them to stop taking remdesivir, while a greater proportion experienced acute kidney injury or liver injury but was able to continue treatment, the study said. "Our findings suggest that at least in a largely Japanese patient population with severe to critical COVID-19, early treatment with remdesivir and corticosteroids is associated with decreased mortality," said Hanafusa. Given the survival benefit demonstrated in this study, the time that has elapsed since symptom onset should be considered when using remdesivir to treat patients who are critically ill with COVID-19. The varying effectiveness of remdesivir at different time points may reflect increasing viral load and lung damage over time and could help explain why the effectiveness of this drug remains controversial. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/fresh-snowfall-keeps-at-least-72-roads-across-himachal-blocked-for-second-week/articleshow/95687672.cms">Fresh snowfall keeps at least 72 roads across Himachal blocked for second week</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/temp-drops-below-freezing-point-in-srinagar/articleshow/95703904.cms">Temp drops below freezing point in Srinagar</a>

Remdesivir could reduce Covid mortality if given within 9 days of symptom onset, says new study

<ul><li>Remdesivir has little or no effect on hospitalised COVID-19 patients, according to a new study by the World Health Organisation (WHO).</li><li>When coronavirus pandemic initially broke, it emerged as one of the most preferred treatments for the disease around the world.</li><li>In July, Gilead released further data suggesting that Remdesivir <a href="https://www.ft.com/content/978b4f8a-62b5-43a0-ad32-dda1930ec47c">may improve chances of survival among COVID-19 patients.</a> However, these findings were not confirmed by a randomised controlled trial until now. </li><li>Even before WHO’s study, a Lancet report <a href="https://www.businessinsider.in/science/health/news/remdesivir-the-coronavirus-miracle-drug-may-be-overhyped-suggests-lancet-study/articleshow/75470476.cms">contradicted </a>Gilead’s claims indicating that the drug may not be the most ‘promising’ treatment for coronavirus.</li><li>Not just Remdesivir, no repurposed drug or combination including Hydroxychloroquine <a href="https://www.nytimes.com/2020/10/15/health/coronavirus-remdesivir-who.html">reduced </a>chances of death of a COVID-19 patient, according to the <keyword id="808941" type="PERSON" weightage="20" keywordseo="WHO-study">WHO study</keyword>. </li></ul>Remdesivir, one of the earliest touted treatments for COVID-19 in the world, is not effective in preventing deaths of coronavirus patients, according to a study sponsored by the World Health Organisation study. The results of the study — <a href="https://www.ft.com/content/ee9b611f-2b4b-4572-afe1-b0b804d17a94">covering</a> over 2,700 people for Remdesivir across 30 countries — were posted online on October 15 and are not peer-reviewed yet. The researchers tried to treat a patient with Remdesivir for 10 days, where each patient received a 200 milligrams (mg) dose on the first day and 100 mg doses on subsequent days. “These Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay,” noted the findings of the WHO’s Solidarity trial that was released on medRxiv. Gildead disagrees with WHO study Remdesivir was originally developed by Gilead Sciences to treat the Ebola virus and Hepatitis C. The company has so far <a href="https://www.nytimes.com/2020/10/15/health/coronavirus-remdesivir-who.html">refuted</a> all the claims made by the WHO study. It asserts that more rigorous studies have found Remdesivir beneficial. “The emerging data appear inconsistent with more robust evidence from multiple randomised, controlled studies validating the clinical benefit of (Remdesivir),” Gilead <a href="https://www.ft.com/content/ee9b611f-2b4b-4572-afe1-b0b804d17a94">said </a>in a comment. WHO has not made in public comment since the study is not public yet. Not just Remdesivir, no repurposed drug or combination including Hydroxychloroquine <a href="https://www.nytimes.com/2020/10/15/health/coronavirus-remdesivir-who.html">reduced </a>chances of death of a COVID-19 patient, according to the WHO study. WHO study brings bad tidings for Remdesivir producers Remdesivir is currently the only antiviral drug <a href="https://www.nytimes.com/2020/10/15/health/coronavirus-remdesivir-who.html">authorised </a>for treating COVID-19 in the US. It was taken by <a href="https://www.businessinsider.in/politics/world/news/trump-baselessly-says-he-may-be-immune-to-covid-19-after-being-hospitalized-and-treated-with-a-steroid-used-for-severe-cases/articleshow/78505594.cms">US President Donald Trump </a>when he was admitted to the hospital after testing positive for the virus. India’s Health Ministry too approved the use of the drug to treat mild cases of coronavirus. However, the drug is not recommended to treat those who have several renal impairments, pregnant and lactating women, children below 12 years age. <table style="border-width: initial; border-style: none; width: 468pt; table-layout: fixed;"></colgroup><tbody><tr><td colspan="3" style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cost of Remdesivir treatment in India </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Company </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Brand </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cost of Therapy </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Hetero </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Covifor </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹32,400 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipla </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipremi </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹24,000 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Jubilant Lifesciences </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">JUBI-R </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹28,200 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cadila Healthcare </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Remdac </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹16,800 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Mylan </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Desrem </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹28,800 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Dr Reddy’s </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Redyx </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹32,400 </td></tr></tbody></table>Source:Nomura report dated October, 2020. There are six pharmaceutical giants in India — including Hetero Labs, Jubilant Lifesciences, Dr. Reddy’s Laboratories, Biocon firm Syngene and Zydus Cadila Healthcare — who have signed a non-exclusive agreement with Gilead to produce Remdesivir. The WHO study is likely to be a setback for all the pharmaceutical companies producing Remdesivir. The increasing number of cases in India drove the demand for Remdesivir. According to industry experts, Remdesivir was bringing in at least ₹6.5 million to ₹13 million in revenues per day at the current caseload. “Assuming 5% to 10% market share, we estimate current demand at 1,200 to 2,400 vials per day, which translates to ₹6.5 million to ₹ 13 million in revenues per day at the current caseload. We factor in ₹1.2 billion and ₹0.9 billion in sales from Remdesivir in FY21F and FY22F respectively,” a Nomura report dated October 2020 said. WHO isn’t alone in its skepticism of Gilead’s Remdesivir Remdesivir emerged as one of the most preferred treatments for COVID-19 — this new found disease that was threatening the world — largely driven by Gilead’s narrative. Even before WHO’s study, a Lancet report <a href="https://www.businessinsider.in/science/health/news/remdesivir-the-coronavirus-miracle-drug-may-be-overhyped-suggests-lancet-study/articleshow/75470476.cms">contradicted</a> the pharmaceutical giant’s claims indicating that Remedesivir may not be the most ‘promising’ treatment for coronavirus. It warned that Remdesivir provided no clinical benefits to patients who have tested for coronavirus. Despite the warnings, Gilead Sciences continue to claim Remdesivir as a plausible treatment for COVID-19. In July, Gilead released further data suggesting that it <a href="https://www.ft.com/content/978b4f8a-62b5-43a0-ad32-dda1930ec47c">may improve chances of survival. </a>However, these findings have not been confirmed by a randomised controlled trial until now. “What all of us would like to see is what is frequently called a ‘magic bullet’; a drug that’s already in existence, that is safe and works effectively in patients. Unfortunately, in this case, this trial at least suggests the benefits of Remdesivir weren’t there at all,” Julie Fischer, an associate research professor in the Department of Microbiology and Immunology at Georgetown University <a href="https://www.aljazeera.com/news/2020/10/16/who-trial-finds-repurposed-drugs-have-little-effect-on-covid-19">told Al Jazeera</a>. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/health/news/chinas-covid-19-coronavirus-is-safe-prompts-antibody-response-says-a-lancet-study/articleshow/78696495.cms">China's COVID-19 coronavirus is safe, prompts antibody response, says Lancet </a>

Remdesivir drug fails to reduce mortality or hospital stay of COVID-19 patients, says WHO study

<ul class="summary-list"><li>A watchdog group says Sen. <keyword id="161182" type="PERSON" weightage="60" keywordseo="Rand-Paul">Rand Paul</keyword> may have intentionally violated the <keyword id="998293" type="PERSON" weightage="60" keywordseo="STOCK-Act">STOCK Act</keyword>, which combats insider trading.</li><li>Paul's wife Kelley purchased stock in Gilead Sciences in February 2020.</li><li>The <keyword id="3961557" type="PERSON" weightage="60" keywordseo="campaign-legal-center">Campaign Legal Center</keyword> is asking the Senate <keyword id="297598" type="ORGANIZATION" weightage="60" keywordseo="ethics-committee">Ethics Committee</keyword> to investigate whether Paul intentionally violated the law.</li></ul>The Campaign Legal Center has filed a <a href="https://campaignlegal.org/sites/default/files/2021-08/CLC_Sen%20Paul_Senate%20Ethics%20Committee%20Complaint.pdf">complaint with the Senate Ethics Committee</a> targeting Republican Sen. Rand Paul of Kentucky, alleging that the senator may have failed to comply with an insider trading law. <a href="https://www.washingtonpost.com/politics/2021/08/11/rand-paul-gilead-stock/?utm_medium=social&amp;utm_source=twitter&amp;utm_campaign=wp_main=wp_main">The Washington Post first reported</a> on Thursday that the senator's wife, Kelley Paul, purchased between $1,000 and $15,000 worth of stock in Gilead Sciences, which manufactures the antiviral drug <keyword id="8775508" type="UNKNOWN" weightage="60" keywordseo="remdesivir">remdesivir</keyword>, in February 2020. Paul disclosed the purchases 16 months after a mandatory 45-day deadline under the Stop Trading on Congressional Knowledge (STOCK) Act, which is designed to combat insider trading by members of congress."This filing, coming over a year late and detailing the financial interest a senator held in a company producing an antiviral drug from the onset of a global pandemic, is a clear example of why greater STOCK Act enforcement is needed," said Kedric Payne, general counsel and senior director of ethics at Campaign Legal Center, <a href="https://campaignlegal.org/press-releases/breaking-campaign-legal-center-files-complaint-against-sen-rand-paul-failure-comply">in a press release.</a>The complaint also noted that Republican Sen. Richard Burr of North Carolina and former Republican Sen. Kelly Loeffler of Georgia made stock trades at roughly the same time. Both faced widespread public criticism and accusations of insider trading. Burr stepped down from his position chairing the Senate Intelligence Committee, while Loeffler lost re-election."Under these circumstances, there is probable cause to believe that Sen. Paul delayed filing his disclosure to avoid similar consequences," said the group's letter to Sens. Chris Coons and James Lankford, who co-chair the ethics committee.Two days before Kelley Paul's purchase, <a href="https://www.who.int/docs/default-source/coronaviruse/transcripts/joint-mission-press-conference-script-english-final.pdf?sfvrsn=51c90b9e_2">an official at the World Health Organization, said</a> the antiviral drug was "one drug right now that we think may have real efficacy."A spokeswoman for the Kentucky senator told the Post that the failure to disclose was an oversight by Paul and that he'd sought the guidance of the Senate Ethics Committee in newly disclosing the purchases. But CLC argues that Sen. Paul's office should've known better."All members of Congress and their staff receive mandatory STOCK Act training-an improper transmission is not an exception under the law," said the press release."If elected officials are not held accountable for failing to promptly and properly disclose stock trades, this trend may continue and worsen, with members delaying disclosure and only facing a nominal fee as a consequence," the press release said.

Sen. Rand Paul may have violated insider trading law by failing to disclose wife's COVID drug stock purchases

Commonly used cholesterol-lowering <keyword id="31644" type="General" weightage="20" keywordseo="statins" source="Orion">statins</keyword> may reduce the risk of death and severity of Covid-19 disease, says a new study. According to the <keyword id="389462" type="General" weightage="80" keywordseo="american-heart-association" source="Orion">American Heart Association</keyword>, one in four Americans over 40 take statins to lower their <keyword id="32472" type="General" weightage="20" keywordseo="cholesterol" source="Orion">cholesterol</keyword> and reduce their risk of heart attack, stroke, and other cardiovascular diseases. "While there is no 'magic bullet' to help patients who are very ill with Covid-19, statins decrease inflammation, which may help reduce the severity of the disease," said lead author Ettore <keyword id="15335892" type="General" weightage="80" keywordseo="crimi" source="Orion">Crimi</keyword> University of Central Florida, Orlando. "Results of our study clearly showed regular statin use is associated with reduced risk of death and improved outcomes in hospitalized Covid-19 patients," Crimi added. For the study, presented at the ANESTHESIOLOGY 2022 annual meeting, the team analysed the electronic medical records of 38,875 patients hospitalised for Covid-19 at 185 hospitals in the US between January 1 and September 30, 2020. Of those patients, 30 per cent regularly used statins to treat high cholesterol. Statin users had a 37 per cent lower risk of dying from Covid-19 than those who did not use statins. In addition, regular statin users were significantly less likely to be discharged to hospice, be admitted to the intensive care unit (ICU) or develop blood clots. They also had shorter hospital stays and spent less time on a ventilator. While Covid-19 causes inflammation, in some cases, the immune system creates further inflammation by responding too aggressively to the infection. This extreme reaction causes much of the damage to the body, including difficulty breathing and damage to the lungs, kidneys, heart, brain and vascular system. The anti-inflammatory actions of statins "cool the process" so that the disease is not as severe, Crimi said. One in four Americans over the age of 40 take statins to lower their cholesterol and reduce their risk of heart attack, stroke and other cardiovascular diseases, according to the American Heart Association, making them one of the most commonly prescribed drugs. SEE ALSO: <a href="https://www.businessinsider.in/business/corporates/news/reliance-reports-a-profit-decline-in-q2-even-as-revenue-surges-33-yoy/articleshow/95017302.cms">Reliance reports a profit decline in Q2 even as revenue surges 33% YoY</a> <a href="https://www.businessinsider.in/business/telecom/news/reliance-jio-reports-4-profit-growth-in-q2-subscriber-addition-arpu-growth-slows-down/articleshow/95017181.cms">Reliance Jio reports 4% profit growth in Q2 – subscriber addition, ARPU growth slows down</a> <a href="https://www.businessinsider.in/stock-market/news/ril-shareholders-to-get-shares-on-11-basis-in-soon-to-be-listed-jfsl/articleshow/95023780.cms">RIL shareholders to get shares on 1:1 basis in soon to be listed JFSL</a>

Cholesterol drug linked to reduced death risk during Covid

<ul><li>Cipla will launch its version of Remdesivir in the next 1-2 days under the brand name 'Cipremi'.</li><li>The drug will be sold at an approximate price of ₹4,000 per vial.</li><li>Remdesivir is considered a key drug in the fight against Covid-19 as a randomised clinical trial conducted with the drug demonstrated faster clinical recovery in hospitalised patients.</li><li>The Union Health Ministry has asked all the states to strengthen their vigil, so that black marketing of Covid-19 drug Remdesivir is prevented.</li></ul>As India faces a shortage of Covid-19 drug Remdesivir, the pharmaceutical company Cipla said it will launch its version of Remdesivir in the next 1-2 days. <a href="https://www.cnbctv18.com/healthcare/exclusive-as-india-faces-shortage-of-remdesivir-cipla-says-its-supplies-will-hit-market-in-next-1-2-days-6281911.htm">In an interview with CNBC TV18</a>, Kedar Upadhyay, Cipla’s CFO said that the Daman-based Sovereign Pharma had released the first batch of the drug from its manufacturing plant and Cipla will be selling it under the brand name 'Cipremi'. While Mumbai-based BDR Pharma holds the contract for manufacturing of Cipla’s Remdesivir, the company has further sub-contracted the manufacturing of the finished dosage and packaging to Daman-based Sovereign Pharma. <div type="Article" hostid="261" msid="76747405" title="These are the companies manufacturing COVID-19 drug Remdesivir in India" mstype="2" mssubtype="0"></div> "We are attempting to launch Remdesivir in the next 1-2 days. We cannot comment on the volumes just as yet, but there is a huge demand-supply gap in the market," Upadhyay told CNBC TV18. However, <a href="https://www.cnbctv18.com/healthcare/exclusive-as-india-faces-shortage-of-remdesivir-cipla-says-its-supplies-will-hit-market-in-next-1-2-days-6281911.htm">reports</a> say that Sovereign Pharma has the capacity to scale up production to 95,000 vials per month. Sovereign Pharma got all necessary approvals for manufacturing the drug within a week, after an inspection by the Central Drugs Standard Control Organisation. The drug will be sold at an approximate price of ₹4,000 per vial. Upadhyay told CNBC that the company is also preparing to set up a Remdesivir manufacturing facility in-house. Remdesivir is considered a key drug in the fight against Covid-19. The drug’s popularity grew after a randomised clinical trial used the drug on 1,063 patients over 60 centres across US, Europe and Asia and saw faster clinical recovery in hospitalised patients. To expand the supply of Remdesivir, US-based Gilead earlier announced non-exclusive voluntary licensing agreements with generic pharmaceutical manufacturers based in India, Egypt and Pakistan. The agreements allow Cipla and other companies including Dr. Reddy's Laboratories Ltd.; Hetero Labs Ltd.; Syngene, a Biocon company; and Zydus Cadila Healthcare Ltd. to manufacture Remdesivir for distribution in 127 countries. Government cracks down on Remdesivir black market The Union Health Ministry has asked all the states to take all measures to ensure that Remdesivir is not sold in the black market. The ministry acted upon it after t<a href="https://www.outlookindia.com/newsscroll/health-ministry-steps-in-to-curb-black-marketing-of-covid-drug/1888995">he Directorate General of Health Services said that it has received </a>a letter from LocalCircles routed through the Health Ministry, raising concerns over black marketing and overpricing of Remdesivir in certain markets. "In view of the above, you are requested to instruct your enforcement officials to keep strict vigil on the matter to prevent black marketing and sale of Remdesivir injection above the MRP," the DGHS said in the letter to the states. SEE ALSO: <a href="https://www.businessinsider.in/science/news/the-us-bought-up-90-of-the-worlds-supply-of-remdesivir-for-the-next-3-months-and-patents-mean-many-countries-wont-be-able-to-get-any/articleshow/76729248.cms" data-type="tilCustomLink">The US bought up 90% of the world's supply of remdesivir for the next 3 months, and patents mean many countries won't be able to get any</a> <a href="https://www.businessinsider.in/stock-market/news/gilead-rises-after-pricing-its-coronavirus-fighting-drug-remdesivir/articleshow/76692239.cms" data-type="tilCustomLink">Gilead rises after pricing its coronavirus-fighting drug remdesivir</a>

Cipla says COVID-19 drug Remdesivir will hit market this week

<ul class="summary-list"><li>Two batches of <keyword id="11893994" type="UNKNOWN" weightage="60" keywordseo="covid-19" source="Orion">COVID-19</keyword> antiviral treatment drug Remdesivir are being recalled.</li><li><keyword id="12678723" type="UNKNOWN" weightage="60" keywordseo="gilead-sciences" source="Orion">Gilead Sciences</keyword> said it received reports of glass particles in some vials linked to the two lots.</li></ul>Two lots of <a href="https://www.businessinsider.com/coronavirus-treatment-gilead-says-positive-data-remdesivir-from-niaid-study-2020-4">COVID-19 antiviral drug Remdesivir</a> have been recalled after glass particles were found in some vials. According to a <a href="https://www.gilead.com/news-and-press/company-statements/gilead-issues-a-voluntary-nationwide-recall-of-two-lots-of-veklury">statement</a> from <keyword id="12678722" type="UNKNOWN" weightage="60" keywordseo="gilead" source="Orion">Gilead</keyword> Sciences, a nationwide recall of two lots of the drug is underway."Gilead Sciences Inc. received a customer complaint, confirmed by the firm's investigation, of the presence of glass particulates," Gilead said in a <a href="https://www.gilead.com/news-and-press/company-statements/gilead-issues-a-voluntary-nationwide-recall-of-two-lots-of-veklury">statement</a>. "An injectable product that contains glass particulates may result in local irritation or swelling in response to the foreign material," the company added. "If the glass particulate reaches the blood vessels it can travel to various organs and block blood vessels in the heart, lungs or brain which can cause stroke and even lead to death." The two lots, 2141001-1A and 2141002-1A, were distributed to wholesalers between October 25 and November 2. Around 55,000 vials of the drug — the equivalent of doses for some 11,000 patients — are involved in this recall, Gilead spokesman Chris Ridley told <a href="https://www.bloomberg.com/news/articles/2021-12-04/gilead-recalls-55-000-vials-of-covid-drug-due-to-glass-shards?utm_campaign=socialflow-organic&amp;utm_content=business&amp;utm_medium=social">Bloomberg News</a>. However, Gilead noted that there had been no adverse reactions reported in connection with the lots recalled. Remdesivir, which is also known as Veklury, is <a href="https://www.businessinsider.com/remdesivir-may-not-significantly-improve-covid-19-outcomes-study-2020-8">one of the FDA-authorized therapies currently available to COVID-19 patients</a> and is <a href="https://www.idsociety.org/covid-19-real-time-learning-network/therapeutics-and-interventions/remdesivir/">given intravenously</a> for ten days. The drug has been used in the US since May 2020, when the FDA <a href="https://www.fda.gov/media/137564/download#:~:text=On%20May%201%2C%202020%2C%20the,Section%20564%20of%20the%20Act.">authorized it for emergency use</a>. <a href="https://www.businessinsider.com/trump-coronavirus-treatment-timeline-remdesivir-antibody-drug-2020-10" target="_blank" rel="noopener">Remdesivir was given to former President Donald Trump when he contracted COVID-19 in October 2020</a>, and it also <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19" target="_blank" rel="noopener">received full FDA approval the same month.</a>It's unclear how many reports Gilead received about glass particles. Gilead did not immediately respond to a request for comment from Insider.

Batches of the COVID-19 treatment drug Remdesivir were recalled after glass particles were found in some vials

Beijing, A chemotherapy medication originally developed to treat <keyword id="63672" type="PERSON" weightage="20" keywordseo="Lymphoma">lymphoma</keyword> has outperformed the popular remdesivir drug against SARS-CoV-2 in lab settings, and could potentially be repurposed to treat <keyword id="8763838" type="UNKNOWN" weightage="20" keywordseo="covid-19">Covid-19</keyword>, say researchers. A novel computational drug screening strategy combined with <keyword id="10531201" type="UNKNOWN" weightage="20" keywordseo="lab-experiments">lab experiments</keyword> suggest that pralatrexate drug is a promising candidate for Covid-19 patients. The novel screening approach identified four promising <keyword id="14721" type="COMPANY" weightage="20" keywordseo="Drugs">drugs</keyword>, which were then tested against SARS-CoV-2 in lab experiments. Two of the drugs, pralatrexate and azithromycin, successfully inhibited replication of the virus. Further lab experiments showed that pralatrexate more strongly inhibited viral replication than did remdesivir, a drug that is currently used to treat some Covid-19 patients, said Haiping Zhang of the <keyword id="10531200" type="UNKNOWN" weightage="20" keywordseo="shenzhen-institutes">Shenzhen Institutes</keyword> of Advanced Technology in <keyword id="95282" type="LOCATION" weightage="20" keywordseo="Shenzhen">Shenzhen</keyword>, China. Zhanh and team screened 1,906 existing drugs for their potential ability to inhibit replication of SARS-CoV-2 by targeting a viral protein called RNA-dependent RNA polymerase (RdRP). The findings, published in open-access journal <keyword id="1318021" type="COMPANY" weightage="20" keywordseo="PLoS-Computational-Biology">PLOS Computational Biology</keyword>, suggest that pralatrexate could potentially be repurposed to treat Covid-19. "However, this chemotherapy drug can prompt significant side effects and is used for people with terminal lymphoma, so immediate use for Covid-19 patients is not guaranteed. Still, the findings support the use of the new screening strategy to identify drugs that could be repurposed," the researchers noted. With the Covid-19 pandemic causing illness and death worldwide, better treatments are urgently needed. One shortcut could be to repurpose existing drugs that were originally developed to treat other conditions. "We have demonstrated the value of our novel hybrid approach that combines deep-learning technologies with more traditional simulations of molecular dynamics," Zhang said. He and his colleagues are now developing additional computational methods for generating novel molecular structures that could be developed into new drugs to treat Covid-19. SEE ALSO: <a href="https://www.businessinsider.in/business/auto/news/kia-motors-11-electric-vehicles-in-2021-but-india-may-have-to-wait-longer-to-buy/articleshow/80056447.cms">INTERVIEW: Kia Motors’ 2021 plan includes 11 electric vehicle launches ⁠— but India may have to wait longer</a> <a href="https://www.businessinsider.in/business/startups/news/india-edtech-in-charts-how-the-shi[%E2%80%A6]es-of-byjus-unacademy-and-others/articleshow/80040270.cms">India’s edtech in charts – How the shift to online learning meant money, valuation and users for the likes of BYJU’S, Unacademy, and others</a> <a href="https://www.businessinsider.in/business/telecom/news/jio-announces-free-domestic-voice-calls-from-january-1/articleshow/80044256.cms">Jio announces free domestic voice calls from January 1</a>

Lymphoma drug outperforms Remdesivir against COVID-19 virus

<keyword id="123712" type="General" weightage="80" keywordseo="metformin" source="Orion">Metformin</keyword>, a commonly prescribed <keyword id="6359018" type="General" weightage="20" keywordseo="diabetes" source="Orion">diabetes</keyword> medication, can help lower the odds of emergency department visits, hospitalisations, or death due to Covid-19 by over 50 per cent if prescribed early in onset of symptoms, finds a study. "Our trial suggests that metformin may reduce the likelihood of needing to go to the emergency room or be hospitalised for Covid-19," said <keyword id="14759788" type="General" weightage="80" keywordseo="carolyn-bramante" source="Orion">Carolyn Bramante</keyword>, Assistant Professor of internal medicine and paediatrics at the <keyword id="5052916" type="General" weightage="50" keywordseo="university-of-minnesota-medical-school" source="Orion">University of Minnesota Medical School</keyword>. The study examined whether metformin, low-dose fluvoxamine, an antidepressant; and ivermectin, an antiparasitic, or their combinations could serve as possible treatments to prevent ER visits or hospitalisation, as well as Long-Covid in 1,323 participants including pregnant women. The findings, published in the <keyword id="401051" type="General" weightage="50" keywordseo="new-england-journal-of-medicine" source="Orion">New England Journal of Medicine</keyword>, found no positive effect from treatment with either ivermectin or low-dose fluvoxamine. The study also included both who were vaccinated and those who were not. "Although we know Covid-19 vaccines are highly effective, we know that some new strains of the virus may evade immunity and vaccines may not be available worldwide. So we felt we should study safe, available and inexpensive outpatient treatment options as soon as possible," said Bramante. "Understanding whether outpatient treatments could ensure more people survive the illness if they contract it and have fewer long-term symptoms is an important piece of the pandemic response. "Observational studies and in vitro experiments cannot be conclusive but do contribute to bodies of evidence," Bramante noted. SEE ALSO : <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/news/india-inc-sees-steepest-decline-in-deal-values-report/articleshow/93658897.cms">India Inc sees steepest decline in deal values: report</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/all-india-consumer-price-index-for-agricultural-rural-labourers-rose-in-july/articleshow/93658813.cms">All-India Consumer Price Index for agricultural, rural labourers rose in July</a>

Diabetes drug effective in reducing severity in Covid patients: Study

Welcome to <a href="http://newsletter.businessinsider.com/join/4np/dispensed-daily">Business Insider</a>'<a href="http://newsletter.businessinsider.com/join/4np/dispensed-daily">s daily healthcare newsletter</a>, your daily dose of pharma, biotech, and <keyword id="6354525" type="UNKNOWN" weightage="100" keywordseo="healthcare">healthcare</keyword> news. <a href="http://newsletter.businessinsider.com/join/4np/dispensed-daily">Subscribe here to get this newsletter in your inbox every weekday.</a>Hello, The <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword> pandemic is overwhelming the US yet again, <a href="https://www.businessinsider.com/trump-says-us-rounding-turn-covid-19-even-cases-surge-2020-10">with the country recording its 2 worst-ever days of infection over the weekend</a>."We are not going to control the pandemic," White House Chief of Staff Mark Meadows <a href="https://www.businessinsider.com/mark-meadows-donald-trump-white-house-coronavirus-treatment-vaccine-2020-10">said Sunday on CNN</a>.Also in healthcare news: <a href="https://www.businessinsider.com/with-fda-approval-gilead-has-a-lucrative-covid-19-drug-in-remdesivir-2020-10">Gilead's set to make billions on a drug that's far from "amazing"</a>, <a href="https://www.businessinsider.com/astrazeneca-oxford-coronavirus-vaccine-trial-can-continue-in-the-us-2020-10">AstraZeneca and Johnson &amp; Johnson have restarted vaccine trials in the US</a>, and <a href="https://www.businessinsider.com/universal-masks-save-lives-mitigate-third-surge-model-2020-10">universal masking could save 130,000. </a><h3><a href="https://www.businessinsider.com/with-fda-approval-gilead-has-a-lucrative-covid-19-drug-in-remdesivir-2020-10"><div type="image" title="Remdesivir2 by Getty Images" height="768" width="1024" msid="78874406" hostid="261"></div></a></h3><h3><a href="https://www.businessinsider.com/with-fda-approval-gilead-has-a-lucrative-covid-19-drug-in-remdesivir-2020-10">Gilead is set to sell billions of dollars of a coronavirus drug that's far from 'amazing' after the US approved remdesivir to treat COVID-19</a></h3><ul><li><keyword id="195727" type="COMPANY" weightage="60" keywordseo="Gilead">Gilead</keyword> Sciences is poised to sell billions of dollars worth of the first COVID-19 treatment approved by US regulators, despite mixed evidence on whether or not the drug actually works.</li><li>A trial conducted earlier this year found hospitalized COVID-19 patients taking <keyword id="8775508" type="UNKNOWN" weightage="60" keywordseo="remdesivir">remdesivir</keyword> recovered modestly faster than those on getting a placebo. The study did not find that the drug reduced deaths in a statistically meaningful way.</li><li><a href="https://www.businessinsider.com/with-fda-approval-gilead-has-a-lucrative-covid-19-drug-in-remdesivir-2020-10">Despite the uncertainty on its efficacy, Wall Street analysts expect the drug to bring in more than $4 billion in revenue over 2020 and 2021.</a></li></ul><a href="https://www.businessinsider.com/with-fda-approval-gilead-has-a-lucrative-covid-19-drug-in-remdesivir-2020-10">Read the full story from Andrew Dunn here&gt;&gt;</a><h3><a href="https://www.businessinsider.com/astrazeneca-oxford-coronavirus-vaccine-trial-can-continue-in-the-us-2020-10"><div type="image" title="astrazeneca covid vaccine" height="683" width="910" msid="78874412" hostid="261"></div></a></h3><h3><a href="https://www.businessinsider.com/astrazeneca-oxford-coronavirus-vaccine-trial-can-continue-in-the-us-2020-10">AstraZeneca and Johnson &amp; Johnson get FDA green light to resume coronavirus vaccine trials in the US after participants got sick</a></h3><ul><li>Two major coronavirus <keyword id="24209" type="PERSON" weightage="60" keywordseo="vaccine">vaccine</keyword> trials — one by AstraZeneca and the University of Oxford, the other by Johnson &amp; Johnson — will resume coronavirus vaccine trials in the US, the companies announced Friday.</li><li>AstraZeneca's late-stage trial had paused September 6 after the company reported "suspected serious adverse reaction" in a UK-based participant.</li><li>Johnson &amp; Johnson halted trials on October 12 after a participant developed an unexplained illness. </li><li><a href="https://www.businessinsider.com/astrazeneca-oxford-coronavirus-vaccine-trial-can-continue-in-the-us-2020-10">The UK resumed clinical trials for AstraZeneca and the University of Oxford vaccines in September, and in Japan earlier this month. </a></li></ul><a href="https://www.businessinsider.com/astrazeneca-oxford-coronavirus-vaccine-trial-can-continue-in-the-us-2020-10">Read the full story from Allana Akhtar here&gt;&gt; </a><a href="https://www.businessinsider.com/universal-masks-save-lives-mitigate-third-surge-model-2020-10"><div type="image" title="Trump-mask" height="1013" width="1351" msid="78874421" hostid="261"></div></a><h3><a href="https://www.businessinsider.com/universal-masks-save-lives-mitigate-third-surge-model-2020-10">Universal mask-wearing could save 130,000 US lives before March, mitigating the worst of this 3rd coronavirus surge</a></h3><ul><li>The US's total coronavirus deaths could surpass 511,000 by the end of February, according to a new University of Washington model.</li><li>Nearly 130,000 of those lives could be saved if 95% of the country wore masks, the model found.</li><li><a href="https://www.businessinsider.com/universal-masks-save-lives-mitigate-third-surge-model-2020-10">Mask-wearing, the researchers wrote, could delay the need for lockdowns and mitigate the worst of the fall-winter surge.</a></li></ul><a href="https://www.businessinsider.com/universal-masks-save-lives-mitigate-third-surge-model-2020-10">Read the full story from Aria Bendix here&gt;&gt;</a>More stories we're reading:<ul><li><a href="https://www.businessinsider.com/why-horseshoe-crab-blood-expensive-2018-8">WATCH: Horseshoe crab blood could help scientists create a coronavirus vaccine. Here's why the liquid is so expensive.</a> (Business Insider)</li><li><a href="https://www.vanityfair.com/news/2020/10/trumps-vaccine-rush-vs-the-fda">An inside look at the FDA's efforts to push back at Trump's rush to a vaccine</a> (Vanity Fair)</li><li><a href="https://www.statnews.com/2020/10/22/blood-plasma-showed-no-benefit-in-covid-19-patients-in-trial/">Blood plasma didn't show benefit in COVID-19 patients, according to a new study</a> (Stat News) </li><li><a href="https://www.wsj.com/articles/why-merck-is-playing-catch-up-in-the-coronavirus-vaccine-chase-11603470832">Merck scientists wanted to get started on vaccine in February, but were overruled by senior execs </a> (The Wall Street Journal)</li></ul><a href="http://newsletter.businessinsider.com/join/4np/newsletter.businessinsider.com/join/4np/insider-healthcare">Subscribe here for daily updates from the healthcare team!</a>- Lydia

You Searched For "remdesivir covid 19 drug" and got 11 results

Is AI dominance inevitable? A technology ethicist says no, actually

PTI

Remain alert says Union Health Minister as India records 3,038 fresh Covid-19 cases

ANI

Remdesivir could reduce Covid mortality if given within 9 days of symptom onset, says new study

PTI

Remdesivir drug fails to reduce mortality or hospital stay of COVID-19 patients, says WHO study

Preeti Soni

Sen. Rand Paul may have violated insider trading law by failing to disclose wife's COVID drug stock purchases

Bryan Metzger

Cholesterol drug linked to reduced death risk during Covid

IANS

Cipla says COVID-19 drug Remdesivir will hit market this week

Navdeep Yadav

Batches of the COVID-19 treatment drug Remdesivir were recalled after glass particles were found in some vials

Cheryl Teh

Lymphoma drug outperforms Remdesivir against COVID-19 virus

IANS

Diabetes drug effective in reducing severity in Covid patients: Study

IANS

The first approved COVID-19 drug is far from 'amazing'

Lydia Ramsey Pflanzer

Popular Keywords

Buying Guides